The mass tort world has just gained a significant new case. Following the September 26th U.S. Judicial Panel on Multidistrict Litigation (JPML) hearing, yesterday’s order officially confirmed the creation of a new mass tort: In re: Angiodynamics, Inc. Port Catheter Product Liability Litigation in the Southern District of California.
The push for centralization came with 58 cases filed across 28 districts, all involving common defendants and key issues of fact and evidence. While defendants sought centralization in New York, the Panel opted for the Southern District of California, where five related cases are already pending.
This litigation revolves around Angiodynamics’ port catheter products, which are used for long-term intravenous access in patients. Allegations include severe complications, such as infections, blood clots, and device malfunctions. According to mass tort attorney and analyst Joseph Fantini, “The centralization of these cases will streamline the legal process, allowing for a more efficient path to justice for the victims.”
If your firm is interested in taking on clients affected by these defective port catheter products, now is the time to get involved. With cases rapidly progressing, your firm can take advantage of this new mass tort opportunity by reaching impacted clients early.
At Blue Sky Legal, we are experts at connecting law firms with high-quality leads for mass tort cases like this one. Our tailored marketing strategies ensure that you can acquire clients efficiently and effectively. Whether through digital or television campaigns, we provide turnkey client acquisition solutions, delivering signed retainers that meet case criteria.
Contact Blue Sky Legal today to discuss how we can support your firm in building a strong caseload for the In re: Angiodynamics litigation, and other high-impact cases.
